What Are the Serious Side Effects of Ozempic?

Ozempic (semaglutide) carries risks that extend well beyond the nausea and upset stomach most users expect. The serious side effects include pancreatitis, gallbladder disease, gastroparesis, kidney injury, vision problems, and emerging psychiatric signals, among others. Some of these are rare but potentially life-threatening, and a few were not fully apparent until millions of prescriptions generated real-world safety data. The picture that has emerged is more complex than a simple list of warnings on a drug label.

Pancreatitis and Severe Gastrointestinal Events

The gastrointestinal tract takes the biggest hit from Ozempic, and not just in the form of the well-known nausea. A large study comparing GLP-1 receptor agonists (the drug class Ozempic belongs to) with another weight-loss medication found that users faced roughly nine times the risk of pancreatitis, about four times the risk of bowel obstruction, and close to four times the risk of gastroparesis.¹ These are relative comparisons, meaning the absolute numbers remain small, but the severity of each condition is what matters. Pancreatitis can be excruciating and, in rare cases, fatal. One case report documented a patient who developed severe acute pancreatitis after four years on semaglutide, leading to distributive shock and death, with a dose increase having occurred just four weeks before admission.² A broader review noted that while acute pancreatitis remained rare across clinical trials, severe postmarketing cases have surfaced now that millions of people are taking these drugs.³

Gastroparesis deserves special attention because it directly stems from how semaglutide works. The drug slows gastric emptying as part of its appetite-suppressing mechanism, but in some people this slowing becomes pathological. Food sits in the stomach for far longer than normal, causing severe bloating, vomiting, and pain. In one documented case, an upper endoscopy found retained food in the stomach more than 24 hours after the patient’s last meal, and the gastroenterology team attributed the gastroparesis directly to semaglutide.⁴ For most people, the stomach-slowing effect is mild and temporary. But if you develop persistent vomiting, a feeling of fullness after eating very little, or upper abdominal pain that does not resolve, gastroparesis is a real possibility worth raising with your doctor.

Gallbladder Disease

Gallstones and gallbladder inflammation are a well-established complication of rapid weight loss regardless of how you lose it, but GLP-1 drugs appear to amplify the problem. A systematic review pooling data from 76 randomized controlled trials found that people taking GLP-1 receptor agonists had a 37% higher relative risk of developing gallbladder disease compared with those not taking the drugs.⁵ The risk was more pronounced at higher doses and with longer treatment duration, and it climbed further when the weight loss itself was more dramatic. That finding creates a frustrating tension: the same higher doses that produce the most impressive weight loss also carry the highest gallstone risk.

If you have had gallbladder problems before, or if you develop sharp pain in the upper right abdomen, particularly after eating fatty food, this is something to take seriously while on Ozempic. Some of these episodes resolve on their own, but cholecystitis (an inflamed gallbladder) can become a surgical emergency.

Vision and Eye Problems

This is an area where the evidence has grown more concerning over time. A condition called nonarteritic anterior ischemic optic neuropathy, or NAION, amounts to a kind of stroke affecting the optic nerve, and it can cause sudden, painless vision loss in one eye. A study of patients with type 2 diabetes found that those prescribed semaglutide or tirzepatide had roughly 1.8 times the rate of NAION compared with a matched group not taking those drugs over a two-year follow-up. The same study found about 1.7 times the rate of other optic nerve disorders in the GLP-1 group.⁶ The absolute numbers were still small (affecting less than one-tenth of one percent of users), but the seriousness of permanent vision loss makes even a small increase alarming.

Separately, patients who already have diabetic retinopathy face a risk of worsening eye disease when starting semaglutide, especially if their blood sugar drops rapidly. Researchers have observed higher rates of proliferative retinopathy progression and new-onset macular edema in this group.⁷ The mechanism seems related to how quickly blood sugar improves rather than to the drug itself, but the practical result is the same: if you have existing eye disease from diabetes, your ophthalmologist needs to be part of the conversation before you start Ozempic.

Kidney Injury

Acute kidney injury has been reported in connection with semaglutide, and the pathway usually runs through the gastrointestinal side effects rather than through the drug attacking the kidneys directly. Severe nausea, vomiting, and diarrhea can lead to dehydration, which in turn stresses the kidneys. In the phase 3b clinical trials for semaglutide, there were eight events of acute kidney injury with semaglutide compared with just one with a competing drug (dulaglutide) and none with either placebo or another comparator (canagliflozin).⁸ The numbers are small, but the implication is practical: if you are vomiting frequently or having persistent diarrhea on Ozempic, staying hydrated is not just about comfort. Dehydration severe enough to damage the kidneys is a real risk, especially in people who already have reduced kidney function or who take other medications that strain the kidneys.

Psychiatric and Mood Effects

This may be the most unsettled area of Ozempic’s safety profile. Pharmacovigilance databases, which collect adverse event reports from healthcare providers and patients, have flagged psychiatric signals for semaglutide. One analysis of the European adverse event database found that among all reports for semaglutide, liraglutide, and tirzepatide, about 1.2% involved psychiatric events. Depression was the most commonly reported psychiatric adverse event, followed by anxiety and suicidal ideation. Women accounted for roughly two-thirds of these reports.⁹

A separate disproportionality analysis of the U.S. FDA’s adverse event reporting system found a statistically significant signal for both depression and suicide/self-injury events with semaglutide specifically, which was not replicated for liraglutide or tirzepatide in the same analysis.¹⁰ Meanwhile, a study using the World Health Organization’s global pharmacovigilance database found elevated reporting ratios for suicidal ideation across semaglutide, liraglutide, and tirzepatide, but interestingly, actual suicide attempts and completed suicides were significantly lower than expected for all of these drugs.¹¹

That contradiction, more reports of suicidal thoughts but fewer actual suicides, is hard to interpret cleanly. It could mean the drugs prompt thoughts without increasing action. It could also reflect reporting biases: patients on a high-profile new drug may be more closely monitored, generating more reports of ideation, while the drug simultaneously improves metabolic health in ways that lower overall mortality risk. The honest answer is that researchers do not yet know whether semaglutide causes depression or suicidal thinking, or whether the signal reflects confounding factors. But it is worth paying attention to your mood, and telling your prescriber if something feels off.

Surgical and Anesthesia Risks

If you are on Ozempic and need surgery, your anesthesiologist needs to know. Because semaglutide slows gastric emptying, your stomach may still contain food or liquid even after you follow standard pre-surgical fasting instructions. That retained stomach content raises the risk of pulmonary aspiration during general anesthesia, which is when stomach contents are inhaled into the lungs, a potentially life-threatening complication.¹² Several anesthesiology organizations have issued guidance recommending that patients pause semaglutide before elective surgery, though the exact timing varies. If you have a procedure coming up, raise this with both your prescriber and your surgical team well in advance.

Muscle Loss and Body Composition

When you lose weight on Ozempic, you are not losing only fat. Research suggests that somewhere between a quarter and 39% of the total weight lost over nine to eighteen months is lean mass, which includes muscle.¹³ Some lean mass loss happens with any weight loss, but these proportions are on the higher end of what researchers typically see with diet and exercise alone. For younger, otherwise healthy adults, this may not be a major concern. But for older adults, losing muscle can accelerate frailty, increase fall risk, and undermine the metabolic benefits the weight loss was supposed to deliver. Resistance training and adequate protein intake are the primary countermeasures, and there is growing recognition among clinicians that these should be prescribed alongside the medication rather than treated as optional lifestyle advice.

Nutritional Deficiencies

Ozempic’s ability to suppress appetite is its main selling point, but eating significantly less food for months or years creates a nutritional gap that many users do not anticipate. A narrative review found that vitamin D deficiency was the most commonly observed abnormality, affecting about 7.5% of users at six months and rising to nearly 14% by one year. Iron depletion was also frequent, with GLP-1 receptor agonist users showing ferritin levels 26% to 30% lower than people on a different class of diabetes medication. More than 60% of users consumed below estimated requirements for both calcium and iron, and average vitamin D intake was only about a fifth of what is recommended.¹⁴ Protein and calcium insufficiency also contributed to the lean mass loss described above, while thiamine and cobalamin (vitamin B12) deficits increased over time.

In extreme cases, the combination of persistent nausea and drastically reduced food intake can lead to Wernicke’s encephalopathy, a neurological emergency caused by severe thiamine deficiency. A systematic review documented case reports of this complication following semaglutide treatment for obesity.¹⁵ Wernicke’s encephalopathy is rare, but it is also preventable with adequate nutrition and supplementation, which makes it the kind of risk that should not catch anyone off guard.

Hair Loss

Thinning hair has become one of the more visible complaints among Ozempic users, and the evidence is firming up. A systematic review found that semaglutide and tirzepatide had the highest incidence rates of hair loss among GLP-1 receptor agonists. The predominant type was telogen effluvium, a form of diffuse shedding that typically occurs a few months after a physiological stressor, in this case, rapid weight loss. The effect appeared dose-dependent: weekly semaglutide doses under 2 mg were rarely implicated, while the higher doses used for obesity treatment were more commonly associated with hair loss. Women were disproportionately affected.¹⁶ The reassuring part is that telogen effluvium is usually reversible once the triggering stressor stabilizes, meaning hair tends to grow back once the rate of weight loss slows and nutritional status improves. But “usually reversible” is cold comfort when you are watching your hair fall out in clumps, and prescribers should be warning patients about this possibility upfront.

Oral Health Effects

A less-discussed set of complications involves the mouth. Semaglutide’s gastrointestinal effects cascade into oral symptoms: dry mouth from reduced saliva production, bad breath linked partly to changes in gut motility and partly to ketosis from reduced food intake, enamel erosion from repeated episodes of vomiting or acid reflux, and altered taste perception.¹⁷ Dry mouth in particular is more than an annoyance. Saliva protects against tooth decay, and chronic xerostomia can significantly increase cavity risk over time. If you are on Ozempic long-term, mentioning the medication to your dentist is a practical step most patients do not think to take.

Thyroid Cancer Concerns

Ozempic’s prescribing information carries a boxed warning about medullary thyroid carcinoma (MTC), the strongest warning category the FDA uses. This warning exists because semaglutide caused thyroid tumors in rodents at high doses. Whether this translates to humans has been debated for years. A systematic review examining thyroid cancer incidence across ten studies involving semaglutide found that thyroid cancer remained very rare, with isolated cases of papillary thyroid cancer and medullary thyroid carcinoma each making up less than 1% of events in their respective study groups.¹⁸ That said, pharmacovigilance data from the global adverse event reporting system flagged medullary thyroid carcinoma as one of the strongest signals for semaglutide, ranking among the top reported events by signal intensity.¹⁹ The practical takeaway: if you or a close family member has a history of medullary thyroid carcinoma or a genetic condition called multiple endocrine neoplasia syndrome type 2, Ozempic is contraindicated. For everyone else, the risk appears very low based on current evidence, but the boxed warning persists because the data cannot definitively rule it out.

Pregnancy and Reproductive Safety

Semaglutide is not approved for use during pregnancy, and manufacturers recommend stopping it at least two months before a planned pregnancy due to its long half-life. The limited human data available so far have not identified a clear increase in major birth defects. One study examining 32 exposed pregnancies found no increased risk of major malformations, though the researchers emphasized that the sample was too small to draw firm conclusions.²⁰ A systematic review reached a similar cautious conclusion: no consistent increased risk of major congenital malformations was identified, but the evidence base was too thin and variable to feel confident about safety.²¹

An additional wrinkle: Ozempic can increase fertility in some women, particularly those with polycystic ovary syndrome, by improving ovulation through weight loss and metabolic improvements. Pharmacovigilance data have even flagged “polycystic ovaries” as a new signal for semaglutide, though this likely reflects the drug’s metabolic effects rather than a harmful outcome.¹⁹ The practical consequence is that women who were not previously ovulating regularly may become pregnant unexpectedly while on the drug, making reliable contraception important for anyone who does not want to conceive.

Weight Regain After Stopping

This is not a side effect in the traditional sense, but it is a serious consequence that affects nearly everyone who stops taking the drug and shapes how you should think about starting it. In the extension of the landmark STEP 1 trial, participants who stopped semaglutide after 68 weeks regained an average of 11.6 percentage points of body weight over the following year. Net weight loss from baseline, including the treatment period and the year off the drug, settled at about 5.6%.²² A meta-analysis comparing different anti-obesity drugs found that semaglutide had the highest absolute weight regain after discontinuation among the medications studied.²³ The implication is that Ozempic works less like a course of antibiotics and more like blood pressure medication: if you stop taking it, the condition it was managing tends to come back. Anyone considering starting should understand that for many people, this is a long-term or indefinite commitment rather than a temporary fix.

Signals Still Being Investigated

Real-world pharmacovigilance data have flagged several adverse events for semaglutide that are not yet listed on the drug’s official label. A comprehensive disproportionality analysis of global safety reports identified new signals including starvation ketoacidosis, chronic cholecystitis, obstructive pancreatitis, allodynia (pain from normally non-painful stimuli), pancreatic enlargement, and chronic pancreatitis, none of which appeared in the drug insert at the time of analysis.¹⁹ Pharmacovigilance signals do not prove causation. They represent patterns in reports that warrant further investigation, and many signals ultimately turn out to be coincidental or confounded by other factors. But some of them, particularly the pancreatic signals, echo concerns already supported by other lines of evidence and deserve close monitoring as more data accumulate.